Contract facts
FederalNo full NAICS 325412 intel page yet. Browse NAICS intelligence
PLUVICTO RADIOPHARMACEUTICAL - CLEVELAND VAMC is a federal award for 250-Network Contract Office 10 (36C250) held by Novartis Pharmaceuticals Corp. Estimated value $400K ($400K obligated). Current period of performance ends Aug 31, 2026. Last award drew 1 bidder. Place of performance: EAST HANOVER NJ.
PLUVICTO RADIOPHARMACEUTICAL - CLEVELAND VAMC
Recompete timing
PublicCurrent PoP ended Aug 31, 2026 (27 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.
Want the durability read on 36C25025F0726? One Pursuit Analysis, $500, inside 48 business hours.
- 48 business hours
- $500
- Credits toward the Pack
Incumbent footprint
Public recordNovartis Pharmaceuticals Corp — $23.5M obligated across 59 awards (firm-wide, all agencies) · lead buyer Department of Veterans Affairs (VA).
Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract 36C25025F0726?
36C25025F0726 (Pluvicto radiopharmaceutical - cleveland VAMC) is a 250-Network Contract Office 10 (36C250) award with a potential value of $400K, currently held by Novartis Pharmaceuticals Corp. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
What is 36C250-25-F-0726?
36C250-25-F-0726 is the dashed form of PIID 36C25025F0726 (Pluvicto radiopharmaceutical - cleveland VAMC), held by Novartis Pharmaceuticals Corp. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.
Which office awarded 36C25025F0726?
250-Network Contract Office 10 (36C250) awarded 36C25025F0726 to Novartis Pharmaceuticals Corp (potential $400K).
Who is the incumbent on 36C25025F0726?
Novartis Pharmaceuticals Corp is the incumbent with $23.5M across 59 related awards in SCOUT’s public footprint. The current period of performance ends Aug 31, 2026.
When does Novartis Pharmaceuticals Corp’s 36C25025F0726 come up for recompete?
SCOUT tracks a period-of-performance end of Aug 31, 2026. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Want the durability read on 36C25025F0726? One Pursuit Analysis, $500, inside 48 business hours.
One Pursuit Analysis is $500 and credits toward the Sprint Pack. Delivery is 48 business hours. Start with the free Exposure Check if you want the list first.
No card · under a minute · then the Sprint menu
Buy one Pursuit Analysis — $500Credits toward the Sprint Pack
Compare plansData: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.